NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Azalea Therapeutics, Inc.

Azalea Therapeutics, Inc.

Private
Berkeley, CaliforniaHealthcare & Life Scienceshttps://azaleatx.com/

Last Round

Series A

Nov 4, 2025

Total Funding Raised

$65M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Azalea Therapeutics, Inc. is a biotechnology company that develops Enveloped Delivery Vehicle (EDV) technology to enable precision in vivo genome engineering for cancer immunotherapies and other immune-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverygene editingCRISPRCAR-T cellsbiopharmatherapeutic developmentin vivo therapyAAV capsidsclinical stage biotechdrug pipelinecell engineeringbiotech startupsmall moleculebiologic therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Azalea Therapeutics, Inc. Comparables

Compare Azalea Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Azalea Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AbbVie
73%
CREATE Medicines
70%
Bristol Myers Squibb
70%

Azalea Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 4, 2025

Key People

Founding team and executive leadership

Jenny Hamilton

Co-Founder, President, and CEO

Founding Team

Andrea van Elsas

Chief Scientific Officer

Executive Team

Azalea Therapeutics, Inc. Investors

Notable investors and investment history

Azalea Therapeutics, Inc. investors
InvestorRounds
RA Capital ManagementSeries A
YosemiteSeries A
Sozo VenturesSeries A
Third Rock VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 26, 2026

    Monthly visitors increased 80% MoM, reaching 8.1K.

  • Nov 4, 2025

    $82M round completed.

Azalea Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Azalea Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Azalea Therapeutics, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersBerkeley, California
Employee Range31
Year Founded2023
Last FundingNov 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.